Liquidia (LQDA) Depreciation & Amortization (CF) (2020 - 2026)

Liquidia's (LQDA) quarterly Depreciation & Amortization (CF) came in at $497000.0 in Q1 2026, up 10.2% year-on-year from $451000.0 in Q1 2025, and up 55.31% quarter-over-quarter from $320000.0 in Q4 2025.

Liquidia (LQDA) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends

Liquidia's Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $497000.0 for Q1 2026.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 10.2% year-over-year to $497000.0 in Q1 2026; TTM through Mar 2026 was $1.6 million, a 27.1% decrease from a year earlier, with the FY2025 full-year figure at $1.5 million, down 30.45% from the prior year.
  • Depreciation & Amortization (CF) grew to $497000.0 in Q1 2026 per LQDA's latest filing, from $320000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.1 million in Q3 2022 and bottomed at $281000.0 in Q2 2025.
  • The 5-year median for Depreciation & Amortization (CF) is $518000.0 (2024), against an average of $591000.0.
  • Across the five-year window, Depreciation & Amortization (CF) tumbled 54.43% in 2023 and climbed 18.68% in 2024, its largest moves.
  • Year by year, Depreciation & Amortization (CF) stood at $566000.0 in 2022, then fell by 10.6% to $506000.0 in 2023, then grew by 2.37% to $518000.0 in 2024, then sank by 38.22% to $320000.0 in 2025, then jumped by 55.31% to $497000.0 in 2026.
  • Per Business Quant, the three latest LQDA Depreciation & Amortization (CF) figures stand at $497000.0 (Q1 2026), $320000.0 (Q4 2025), and $476000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 239.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 119.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 1.04 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 22.60 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 676.10 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 7.20 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 172.00 Mn
10 Liquidia 7.84 Bn 7.61 Bn 121.79 Mn 497,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 497,000.00
Mar 31, 2026 497,000.00
Dec 31, 2025 320,000.00
Dec 31, 2025 320,000.00
Sep 30, 2025 476,000.00
Sep 30, 2025 476,000.00
Jun 30, 2025 281,000.00
Jun 30, 2025 281,000.00
Mar 31, 2025 451,000.00
Mar 31, 2025 451,000.00
Dec 31, 2024 518,000.00
Dec 31, 2024 518,000.00
Sep 30, 2024 610,000.00
Sep 30, 2024 610,000.00
Jun 30, 2024 580,000.00
Jun 30, 2024 580,000.00
Mar 31, 2024 489,000.00
Mar 31, 2024 489,000.00
Dec 31, 2023 506,000.00
Dec 31, 2023 506,000.00